论文部分内容阅读
对280例食管癌患者进行平消片加放疗与单纯放射治疗随机分组疗效观察,两组照射剂量、方法,分割因素相同。DT65—70GY/6—7周完成全疗程,综合组放疗开始服用平消片,每日3次,每次4片,连续服用放疗结束后3个月以上。本文结果:1、2、3年生存率,综合组为68.6％,50.7％,37.9％;对照组55.7％,37.1％,19.3%,差异显著(P<0.05),局部复发,颈部淋巴结转移,远处转移,综合组分别为52.1％,11.4％,5.7％,对照组分别为70％,25.7％,13.6％,差异显著,(P<0.05)。综合组提高了生存率与生存质量,局部复发和转移明显降低,
For 280 patients with esophageal cancer, randomized grouping of Pingshu Tablet plus radiotherapy and radiotherapy alone was performed. The doses, methods, and segmentation factors of the two groups were the same. DT65-70GY/6-7 weeks to complete the full course of treatment, comprehensive group radiotherapy began to take Pingxiao tablets, 3 times a day, 4 tablets each time, more than 3 months after the end of continuous radiotherapy. In this study, the 1-, 2-, and 3-year survival rates were 68.6%, 50.7%, and 37.9% in the comprehensive group, and 55.7%, 37.1%, and 19.3% in the control group, respectively. There was a significant difference (P<0.05), local recurrence, and cervical lymph node metastasis. The distant metastases were 52.1%, 11.4%, and 5.7% in the comprehensive group and 70%, 25.7%, and 13.6% in the control group, respectively (P<0.05). The comprehensive group improved the survival rate and quality of life, and local recurrence and metastasis decreased significantly.